Cost of treating patients with smoking history in a specialized cancer hospital;Custo do tratamento de pacientes com histórico de tabagismo em hospital especializado em câncer

Revista de Saude Publica

Volumn 45, Issue 3, 2011, Pages 575-582

  Pinto, Márcia ^a   Ugá, Maria Alicia Domínguez ^a  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

Author keywords

Cohort Studies; Health Care Costs; Neoplasms; Smoking

Indexed keywords

ARTICLE; BRAZIL; CANCER STAGING; COHORT ANALYSIS; ECONOMICS; ESOPHAGUS TUMOR; FEMALE; HEALTH CARE COST; HOSPITALIZATION; HUMAN; LARYNX TUMOR; LONGITUDINAL STUDY; LUNG TUMOR; MALE; MIDDLE AGED; SMOKING;

BRAZIL; COHORT STUDIES; ESOPHAGEAL NEOPLASMS; FEMALE; HEALTH CARE COSTS; HOSPITALIZATION; HUMANS; LARYNGEAL NEOPLASMS; LONGITUDINAL STUDIES; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; SMOKING;

EID: 79959730707     PISSN: 00348910     EISSN: None     Source Type: Journal    
DOI: 10.1590/S0034-89102011005000026     Document Type: Article

References (24)

1. Arnold D, Funk GF, Karnell LH, Chen AH, Hoffman HT, Ricks JM, et al. Laryngeal cancer cost analysis: association of case-mix and treatment characteristics with medical charges. Laryngoscope. 2000;110(1):1-7. DOI:10.1097/00005537-200001000-00001.
2. Brinkman GL, Coates Jr EO. The effects of bronchitis, smoking and occupation on ventilation. Ann Rev Respir Dis. 1963;87:684-93.
3. Cersosimo RJ. Lung cancer: a review. Am J Health Syst Pharm. 2002;59(7):611-42.
4. Corrêa PCRP, Barreto SM, Passos VMA. Smokingattributable mortality and years of potential life lost in [16] Brazilian capitals, 2003: a prevalence-based study. BMC Public Health. 2009;9:206. DOI:10.1186/1471-2458-9-206
5. Danaei G, Vander Hoorn S, Lopez AD, Murray CJL, Ezzati M. Causes of cancer in the world: comparative risk assessment of nine behavioural and environmental risk factors. Lancet. 2005;366(9499):1784-93. DOI:10.1016/S0140-6736(05)67725-2.
6. Dedes KJ, Szucs TD, Bodis S, Joerger M, Lowy A, Russi EW, et al. Management and costs of treating lung cancer patients in a universitary hospital. Pharmacoeconomics. 2004;22(7):435-44.
7. Haire-Joshu D, Glasgow RE, Tibbs TL. Smoking and diabetes. Diabetes Care. 1999;22(11):1887-98. DOI:10.2337/diacare.22.11.1887.
8. Hillner BE, McDonald MK, Desch CE, Smith TJ, Penberthy L, Maddox P, et al. Costs of care associated with non-small-cell lung cancer in a commercially insured cohort. J Clin Oncol. 1998;16(4):1420-4.
9. Izumi Y, Tsuji I, Ohkubo T, Kuwahara A, Nishino, Hisamichi S. Impact of smoking habit on medical care and its costs: a prospective observation of National Health Insurance beneficiaries in Japan. Int J Epidemiol. 2001;30(3):616-21. DOI:10.1093/ije/30.3.616.
10. Janssen-Heijnen MLG, Schipper RM, Razemberg PPA, Crommelin MA, Coebergh JWW. Prevalence of comorbidity in lung cancer patients and its relationship with treatment: a population-based study. Lung Cancer. 1998; 21(2):105-13.
11. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006;3(11):e442. DOI:10.1371/journal.pmed.0030442.
12. Medici AC, Marques RM. Sistemas de custos como instrumento de eficiência e qualidade dos serviços de saúde. Cad Fundap. 1996;(19):47-59.
13. Neubauer S, Welte R, Beiche A, Koenig HH, Buesch K, Leidl R. Mortality, morbidity and costs attributable to smoking in Germany: update and a 10-year comparison. Tob Control. 2006;15(6):464-71. DOI:10.1136/tc.2006.016030.
14. Oliveira AF, Valente JG, Leite IC. Aspectos da mortalidade atribuível ao tabaco: revisão sistemática. Rev Saude Publica. 2008;42(2):335-45. DOI:10.1590/S0034-89102008005000001.
15. o ed. Atlanta: American Cancer Society; 2009.
16. Soni A, Sonnenberg A. Health resource utilization in the management of oesophageal adenocarcinoma. Aliment Pharmacol Ther. 2001;15(7):945-51. DOI:10.1046/j.1365-2036.2001.01004.x.
17. Stewart BW, Kleihues P, editors. World cancer report. Lyon: IARC Press; 2003.
18. Thuler FP, Forones NM, Ferrari AP. Neoplasia avançada de esôfago: diagnóstico ainda muito tardio. Arq Gastroenterol. 2006;43(3):206-11. DOI:10.1590/S0004-28032006000300010.
19. Toh CK, Gao F, Lim WT, Leong SS, Fong KW, Yap SP, et al. Never-smokers with lung cancer: epidemiologic evidence of a distinct disease entity. J Clin Oncol. 2006;24(15):2245-51. DOI:10.1200/JCO.2005.04.8033
20. Tomasich FDS, Valladares GCG, Demarchi VCA, Gagliardi D. Influência do tratamento neoadjuvante na morbi-mortalidade das esofagectomias. Rev Assoc Med Bras. 2003;49(3):300-5. DOI:10.1590/S0104-42302003000300035.
21. US Department of Health and Human Services. Reducing the health consequences of smoking: 25 years of progress: a report of the surgeon general. Rockville, MD: Public Health Service, Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 1989. (DHHS Publication, 89-8411).
22. Van Agthoven, van Inevel BM, de Boer MF, Leemans CR, Knegt PP, Snow GB, et al. The costs of head and neck oncology: primary tumors, recurrent tumors longterm follow-up. Eur J Cancer. 2001;37(17):2204-11.
23. Wolstenholme JL, Whynes DK. The hospital costs of treating lung cancer in the United Kingdom. Br J Cancer. 1999;80(1/2):215-8. DOI:10.1038/sj.bjc.6690341.
24. Wünsch Filho V. The epidemiology of laryngeal cancer in Brazil. Sao Paulo Med J. 2004;122(5):188-94. DOI:10.1590/S1516-31802004000500002.